Results 21 to 30 of about 740 (167)

Next Generation Therapeutics for the Treatment of Myelofibrosis

Cells, 2021
Myelofibrosis is a myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, bone marrow fibrosis, and a propensity towards transformation to acute leukemia.
Douglas Tremblay, John Mascarenhas
doaj   +2 more sources

Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm [PDF]

Leukemia Research Reports
Presented here is the case of a 68-year-old woman with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG) maintenance therapy post-allogeneic hematopoietic stem cell transplantation (allo-HCT).
Qaiser Bashir, Marina Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar Qazilbash, Naveen Pemmaraju   +13 more
doaj   +2 more sources

Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting [PDF]

Journal of Immunotherapy and Precision Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options.
Prajwal Dhakal, Mario Sy, Grerk Sutamtewagul, Eric Mou, Nanmeng Yu, Naveen Pemmaraju   +5 more
doaj   +2 more sources

Case Report: A rare RUNX1 rearrangement resulting from t(8;21)(p12;q22) in acute myeloid leukemia with plasmacytoid dendritic cell expansion [PDF]

Frontiers in Oncology
In recent years, acute myeloid leukemia with plasmacytoid dendritic cell expansion (pDC-AML) has been recognized as a rare provisional subtype of AML, comprising approximately 3–5% of all reported cases and associated with a poorer clinical outcome ...
Jinying Gong, Jinying Gong, Jialong Liu, Lisha Lu, Lisha Lu, Jiru Wei, Xue Wu, Junyan Zou, Yuan Feng, Guoqing Zhu, Guoqing Zhu, Jing Han   +11 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature

Swiss Medical Weekly
INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available.
Ramona Meier-Lienhard, Cosima Suter, Thomas Pabst, Felicitas Hitz, Jakob R. Passweg, Olivier Spertini, Nathan Cantoni, Daniel Betticher, Lucas Simeon, Michael Medinger, Stefanie Hayoz, Adrian Schmidt   +11 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm presenting as a scalp hematoma [PDF]

JAAD Case Reports
Eduardo A. Michelen-Gómez, MD, Karina Cancel-Artau, MD, Cristina P. Gerena-Maldonado, MD, Iancarlos Jiménez-Sacarello, MD, María Rivera-Rolón, MD, Julio E. Sánchez-Pont, MD, Rafael F. Martín-García, MD   +6 more
doaj   +2 more sources

Tagraxofusp-erzs [PDF]

, 2020
openaire   +2 more sources

Tagraxofusp

Reactions Weekly
core   +4 more sources

Impressive Skin and Systemic Response Despite Patient Underestimation and Delayed Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]

Case Rep Hematol
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy derived from precursors of plasmacytoid dendritic cells (pDCs), most frequently presenting with cutaneous involvement and often progressing to bone marrow (BM), lymph node, and central nervous system (CNS) infiltration.
Pacini E, Esposito Vangone B, Santoni A, Malchiodi M, Zuanelli Brambilla C, Sicuranza A, Beffa G, Bocchia M.   +7 more
europepmc   +2 more sources

First-line tagraxofusp induces durable responses with prolonged survival in adults younger than 50 years with blastic plasmacytoid dendritic cell neoplasm: Post hoc analysis of a phase 2 trial. [PDF]

Br J Haematol
British Journal of Haematology, Volume 207, Issue 6, Page 2592-2596, December 2025.
Stein AS, Lane AA, Sweet KL, Vasu S, Tosolini A, Katsetos J, Konopleva M, Pemmaraju N.   +7 more
europepmc   +2 more sources